Comparative Pharmacology
Head-to-head clinical analysis: MACRILEN versus R GENE 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACRILEN versus R GENE 10.
MACRILEN vs R-GENE 10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MACRILEN (macimorelin) is a synthetic growth hormone secretagogue receptor (GHS-R) agonist that stimulates growth hormone (GH) release from the anterior pituitary. It mimics the action of ghrelin, enhancing GH secretion through GHS-R activation.
Arginine is a semi-essential amino acid that serves as a substrate for nitric oxide (NO) synthesis via nitric oxide synthase (NOS), leading to vasodilation. It also stimulates growth hormone release and is involved in the urea cycle for ammonia detoxification.
1 mg subcutaneously once daily, titrated as needed to a maximum of 2 mg daily.
10 mg intravenously over 1-2 minutes, once daily for 5 days, repeat course after 2-3 weeks if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours (range 2.5–4.5 hours) in healthy adults. This short half-life supports its use for diagnostic testing, with rapid clearance after stimulation of growth hormone release.
Terminal elimination half-life is 2-4 hours (mean 3 hours) in adults with normal renal function; prolonged to 8-18 hours in renal impairment.
Primarily renal; approximately 90% of the administered dose is excreted unchanged in urine within 24 hours. Less than 5% is metabolized, with metabolites also eliminated renally. Fecal excretion is negligible (<2%).
Primarily renal (approximately 80-90% unchanged). Biliary/fecal elimination accounts for <5%.
Category C
Category C
Diagnostic Agent
Diagnostic Agent